There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ironwood Pharma (IRWD) and Intercept Pharma (ICPT) with bullish sentiments.
Ironwood Pharma (IRWD)
In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Ironwood Pharma, with a price target of $23. The company’s shares opened today at $12.78, close to its 52-week low of $12.67.
Rivkind Koffler commented:
“We remain Buy rated and summarize 3Q:18 results in Exhibit 1.”
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 8.2% and a 44.0% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Supernus Pharmaceuticals.
Currently, the analyst consensus on Ironwood Pharma is a Moderate Buy with an average price target of $17.50, implying a 36.9% upside from current levels. In a report issued on October 31, Wells Fargo also maintained a Buy rating on the stock with a $18.50 price target.
.
See today’s analyst top recommended stocks >>
Intercept Pharma (ICPT)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Intercept Pharma today and set a price target of $220.48. The company’s shares opened today at $109.37.
According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -8.2% and a 35.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.
Intercept Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $140.81, a 28.7% upside from current levels. In a report issued on October 31, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $170 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
